Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells: A snapshot of IL-6 mediated involvement

Cancer Letters

Volumn 375, Issue 1, 2016, Pages 51-61

  Bharti, Rashmi ^a   Dey, Goutam ^a   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Cancer stem cell; Chemoresistance and EMT; Cytokine; IL 6

Indexed keywords

ATIPRIMOD; CISPLATIN; GEMCITABINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; NERVE CELL ADHESION MOLECULE; PACLITAXEL; PROTEIN KINASE B; STAT3 PROTEIN; TAMOXIFEN; TOCILIZUMAB; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VIMENTIN; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG RESISTANCE; ENDOMETRIUM CANCER; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GLIOBLASTOMA; GLIOMA; HUMAN; LIVER CELL CARCINOMA; MALIGNANT TRANSFORMATION; MELANOMA; MESENCHYMAL STEM CELL; METASTASIS; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL; STOMACH CANCER; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; ANIMAL; CANCER STEM CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERLEUKIN-6; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84960172248     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.02.048     Document Type: Review

References (142)

1. Cohen S., Bruchim I., Graiver D., Evron Z., Oron-Karni V., Pasmanik-Chor M., et al. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J. Mol. Med 2013, 91:357-368.
2. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
3. Middleton K., Jones J., Lwin Z., Coward J.I. Interleukin-6: an angiogenic target in solid tumours. Crit. Rev. Oncol. Hematol 2013.
4. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther 2013.
5. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
6. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007, 9.
7. Bharti R., Dey G., Ojha P.K., Rajput S., Jaganathan S.K., Sen R., et al. Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer. Oncogene 2015.
8. Nguyen D.P., Li J.Y., Tewari A.K. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int 2014, 113:986-992.
9. Guo Y.Q., Xu F., Lu T.H., Duan Z.F., Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev 2012, 38:904-910.
10. Garcia-Tunon I., Ricote M., Ruiz A., Fraile B., Paniagua R., Royuela M. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. Histopathology 2005, 47:82-89.
11. Dey G., Bharti R., Sen R., Mandal M. Microbial amphiphiles: a class of promising new-generation anticancer agents. Drug Discov. Today 2015, 20:136-146.
12. Hartman Z.C., Poage G.M., den Hollander P., Tsimelzon A., Hill J., Panupinthu N., et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 2013, 73:3470-3480.
13. Barbieri I., Pensa S., Pannellini T., Quaglino E., Maritano D., Demaria M., et al. Constitutively active stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of cten. Cancer Res 2010, 70:2558-2567.
14. Hollingshead B.D., Beischlag T.V., DiNatale B.C., Ramadoss P., Perdew G.H. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res 2008, 68:3609-3617.
15. Kolasa E., Houlbert N., Balaguer P., Fardel O. AhR- and NF-kappaB-dependent induction of interleukin-6 by co-exposure to the environmental contaminant benzanthracene and the cytokine tumor necrosis factor-alpha in human mammary MCF-7 cells. Chem. Biol. Interact 2013, 203:391-400.
16. Ndlovu M.N., Van Lint C., Van Wesemael K., Callebert P., Chalbos D., Haegeman G., et al. Hyperactivated NF-kappa B and AP-1 transcription factors promote highly accessible chromatin and constitutive transcription across the interleukin-6 gene promoter in metastatic breast cancer cells. Mol. Cell. Biol 2009, 29:5488-5504.
17. Sasser A.K., Sullivan N.J., Studebaker A.W., Hendey L.F., Axel A.E., Hall B.M. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J. 2007, 21:3763-3770.
18. Leslie K., Gao S.P., Berishaj M., Podsypanina K., Ho H., Ivashkiv L., et al. Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res 2010, 12.
19. Chang Q., Bournazou E., Sansone P., Berishaj M., Gao S.P., Daly L., et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013, 15:848-862.
20. Studebaker A.W., Storci G., Werbeck J.L., Sansone P., Sasser A.K., Tavolari S., et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008, 68:9087-9095.
21. Nagasaki T., Hara M., Nakanishi H., Takahashi H., Sato M., Takeyama H. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Brit. J. Cancer 2014, 110:469-478.
22. De Luca A., Lamura L., Gallo M., Maffia V., Normanno N. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J. Cell. Biochem 2012, 113:3363-3370.
23. Molloy A.P., Martin F.T., Dwyer R.M., Griffin T.P., Murphy M., Barry F.P., et al. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int. J. Cancer 2009, 124:326-332.
24. Rokavec M., Wu W.L., Luo J.L. IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol. Cell 2012, 45:777-789.
25. Sethi N., Dai X.D., Winter C.G., Kang Y.B. Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
26. Hefler L.A., Grimm C., Lantzsch T., Lampe D., Leodolter S., Koelbl H., et al. Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in Caucasian women. Clin. Cancer Res 2005, 11:5718-5721.
27. Oh K., Lee O.Y., Shon S.Y., Nam O., Ryu P.M., Seo M.W., et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res 2013, 15.
28. Lee Y.W., Hirani A.A., Kyprianou N., Toborek M. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells. Inflamm. Res 2005, 54:380-389.
29. Smith H.O., Stephens N.D., Qualls C.R., Fligelman T., Wang T., Lin C.Y., et al. The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma. Mol. Oncol 2013, 7:41-54.
30. Che Q., Liu B.Y., Wang F.Y., He Y.Y., Lu W., Liao Y., et al. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-kappa B signaling pathway. Biochem. Bioph. Res. Co 2014, 446:167-172.
31. Wang Y., Li L., Guo X., Jin X., Sun W., Zhang X., et al. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012, 59:228-236.
32. Ren C.X., Cheng X., Lu B., Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur. J. Cancer 2013, 49:3889-3899.
33. Abdelwahab S.I., Abdul A.B., Zain Z.N., Hadi A.H. Zerumbone inhibits interleukin-6 and induces apoptosis and cell cycle arrest in ovarian and cervical cancer cells. Int. Immunopharmacol 2012, 12:594-602.
34. Mejias-Luque R., Peiro S., Vincent A., Van Seuningen I., de Bolos C. IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim. Biophys. Acta 2008, 1783:1728-1736.
35. Lin M.T., Lin B.R., Chang C.C., Chu C.Y., Su H.J., Chen S.T., et al. IL-6 induces AGS gastric cancer cell invasion via activation of the c-Src/RhoA/ROCK signaling pathway. Int. J. Cancer 2007, 120:2600-2608.
36. He G.B., Dhar D., Nakagawa H., Font-Burgada J., Ogata H., Jiang Y.H., et al. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling. Cell 2013, 155:384-396.
37. Su Y.C., Li S.C., Wu Y.C., Wang L.M., Chao K.S., Liao H.F. Resveratrol downregulates interleukin-6-stimulated sonic hedgehog signaling in human acute myeloid leukemia. Evid. Based Complement. Alternat. Med 2013, 2013:547430.
38. Wang X.H., Lee S.O., Xia S.J., Jiang Q., Luo J., Li L., et al. Endothelial cells enhance prostate cancer metastasis via IL-6 -> Androgen Receptor -> TGF-beta -> MMP-9 Signals. Mol. Cancer Ther 2013, 12:1026-1037.
39. Neiva K.G., Warner K.A., Campos M.S., Zhang Z.C., Moren J., Danciu T.E., et al. Endothelial cell-derived interleukin-6 regulates tumor growth. BMC Cancer 2014, 14.
40. Park E.J., Lee J.H., Yu G.Y., He G.B., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
41. Ohishi W., Cologne J.B., Fujiwara S., Suzuki G., Hayashi T., Niwa Y., et al. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int. J. Cancer 2014, 134:154-163.
42. Che Q., Liu B.Y., Liao Y., Zhang H.J., Yang T.T., He Y.Y., et al. Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17 beta-estradiol biosynthesis in endometrial carcinoma microenvironment. Int. J. Cancer 2014, 135:282-294.
43. Abulaiti A., Shintani Y., Funaki S., Nakagiri T., Inoue M., Sawabata N., et al. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-beta signaling by IL-6. Lung Cancer 2013, 82:204-213.
44. Chen M.F., Chen P.T., Lu M.S., Lin P.Y., Chen W.C., Lee K.D. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol. Cancer 2013, 12.
45. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer (vol 15, pg 103, 2009). Cancer Cell 2009, 15:241.
46. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., et al. gp130-mediated stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
47. Tu B., Du L., Fan Q.M., Tang Z., Tang T.T. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett 2012, 325:80-88.
48. Wang Z.G., Si X.L., Xu A., Meng X.N., Gao S.L., Qi Y.J., et al. Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-Type cytokine signaling correlates with clinical implications. PLoS ONE 2013, 8.
49. McFarland B.C., Hong S.W., Rajbhandari R., Twitty G.B., Gray G.K., Yu H., et al. NF-kappa B-Induced IL-6 Ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS ONE 2013, 8.
50. Kesanakurti D., Chetty C., Dinh D.H., Gujrati M., Rao J.S. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with alpha 5 beta 1 integrin in glioma. Oncogene 2013, 32:327-340.
51. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
52. Xie J.Y., Li M.X., Xiang D.B., Mou J.H., Qing Y., Zeng L.L., et al. Elevated expression of APE1/Ref-1 and its regulation on IL-6 and IL-8 in bone marrow stromal cells of multiple myeloma. Clin. Lymphoma Myeloma Leuk 2010, 10:385-393.
53. Wani A.A., Jafarnejad S.M., Zhou J., Li G. Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappa B/interleukin-6 signaling pathway. Oncogene 2011, 30:2778-2788.
54. Reynaud D., Pietras E., Barry-Holson K., Mir A., Binnewies M., Jeanne M., et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 2011, 20:661-673.
55. Brady J.J., Li M., Suthram S., Jiang H., Wong W.H., Blau H.M. Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat. Cell Biol 2013, 15:U1244-U1272.
56. Wang H., Lathia J.D., Wu Q.L., Wang J.L., Li Z.Z., Heddleston J.M., et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27:2393-2404.
57. Cui X.R., Liu J.P., Bai L., Tian J., Zhu J. Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3. Cancer Sci 2014, 105:64-71.
58. Islam M., Sharma S., Teknos T.N. RhoC regulates cancer stem cells in head and neck squamous cell carcinoma by overexpressing IL-6 and phosphorylation of STAT3. PLoS ONE 2014, 9.
59. Krishnamurthy S., Warner K.A., Dong Z.H., Imai A., Nor C., Ward B.B., et al. Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells 2014, 32:2845-2857.
60. Sung S.Y., Liao C.H., Wu H.P., Hsiao W.C., Wu I.H., Yu J.P., et al. Loss of let-7 MicroRNA Upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS ONE 2013, 8.
61. Zhu Q., Zhang X., Zhang L., Li W., Wu H., Yuan X., et al. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell Death Dis 2014, 5:e1295.
62. Rattigan Y., Hsu J.M., Mishra P.J., Glod J., Banerjee D. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res 2010, 316:3417-3424.
63. Bian Z.Y., Fan Q.M., Li G., Xu W.T., Tang T.T. Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2. Cancer Sci 2010, 101:2554-2560.
64. Kim S.Y., Kang J.W., Song X.X., Kim B.K., Yoo Y.D., Kwon Y.T., et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell. Signal 2013, 25:961-969.
65. Iliopoulos D., Hirsch H.A., Wang G.N., Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 2011, 108:1397-1402.
66. Ibrahim S.A., Hassan H., Vilardo L., Kumar S.K., Kumar A.V., Kelsch R., et al. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS ONE 2013, 8:e85737.
67. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest 2007, 117:3988-4002.
68. Marotta L.L.C., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest 2011, 121:2723-2735.
69. Liu C.C., Lin J.H., Hsu T.W., Su K., Li A.F., Hsu H.S., et al. IL-6 enriched lung cancer stem-like cell population by inhibition of cell cycle regulators via DNMT1 upregulation. Int. J. Cancer 2014.
70. Zhang J., Pan Y.F., Ding Z.W., Yang G.Z., Tan Y.X., Yang C., et al. RMP promotes venous metastases of hepatocellular carcinoma through promoting IL-6 transcription. Oncogene 2014, 0.
71. Zhu L.M., Cheng X.J., Ding Y.F., Shi J.D., Jin H.Y., Wang H., et al. Bone marrow-derived myofibroblasts promote colon tumorigenesis through the IL-6/JAK2/STAT3 pathway. Cancer Lett 2014, 343:80-89.
72. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks (vol 71, pg 614, 2011). Cancer Res 2011, 71:2407.
73. Xie G.Z., Yao Q.W., Liu Y., Du S.S., Liu A.H., Guo Z.Z., et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int. J. Oncol 2012, 40:1171-1179.
74. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappa B, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
75. Anello L.D., Sansone P., Storci G., Mitrugno V., Uva G.D., Chieco P., et al. Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol. Cancer 2010, 9.
76. Yadav A., Kumar B., Datta J., Teknos T.N., Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res 2011, 9:1658-1667.
77. Qureshi R., Arora H., Rizvi M.A. EMT in cervical cancer: its role in tumour progression and response to therapy. Cancer Lett 2014.
78. Rokavec M., Oner M.G., Li H.H., Jackstadt R., Jiang L.C., Lodygin D., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Invest 2014, 124:1853-1867.
79. Colomiere M., Ward A.C., Riley C., Trenerry M.K., Cameron-Smith D., Findlay J., et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. Cancer 2009, 100:134-144.
80. Chen W., Gao Q., Han S., Pan F., Fan W. The CCL2/CCR2 axis enhances IL-6-induced epithelial-mesenchymal transition by cooperatively activating STAT3-Twist signaling. Tumour Biol 2014.
81. Zhao Z.Q., Cheng X.M., Wang Y.B., Han R., Li L., Xiang T., et al. Metformin inhibits the IL-6-Induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS ONE 2014, 9.
82. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28:2940-2947.
83. Chia C.Y., Kumari U., Casey P.J. Breast cancer cell invasion mediated by Galpha12 signaling involves expression of interleukins-6 and -8, and matrix metalloproteinase-2. J. Mol. Signal 2014, 9:6.
84. Rojas A., Liu G., Coleman I., Nelson P.S., Zhang M., Dash R., et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 2011, 30:2345-2355.
85. Che D.H., Pan B., Tian Q., Shang L.H., Liu F., Jin S., et al. Enhanced invasion of lung adenocarcinoma cells after co-culture with THP-1-derived macrophages via the induction of EMT by IL-6. Immunol. Lett 2014, 160:1-10.
86. Hatziapostolou M., Polytarchou C., Aggelidou E., Drakaki A., Poultsides G.A., Jaeger S.A., et al. An HNF4 alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011, 147:1233-1247.
87. Miao J.W., Liu L.J., Huang J. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. Int. J. Oncol 2014, 45:165-176.
88. Guan J., Zhang H., Wen Z., Gu Y.M., Cheng Y., Sun Y., et al. Retinoic acid inhibits pancreatic cancer cell migration and EMT through the downregulation of IL-6 in cancer associated fibroblast cells. Cancer Lett 2014, 345:132-139.
89. Brighenti E., Calabrese C., Liguori G., Giannone F.A., Trere D., Montanaro L., et al. Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer. Oncogene 2014, 33:4396-4406.
90. Luo F., Xu Y., Ling M., Zhao Y., Xu W.C., Liang X., et al. Arsenite evokes IL-6 secretion, autocrine regulation of STAT3 signaling, and miR-21 expression, processes involved in the EMT and malignant transformation of human bronchial epithelial cells. Toxicol. Appl. Pharm 2013, 273:27-34.
91. Chen M.F., Wang W.H., Lin P.Y., Lee K.D., Chen W.C. Significance of the TGF-beta1/IL-6 axis in oral cancer. Clin. Sci. (Lond.) 2012, 122:459-472.
92. Shiota M., Bishop J.L., Nip K.M., Zardan A., Takeuchi A., Cordonnier T., et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013, 73:3109-3119.
93. Chuang M.J., Sun K.H., Tang S.J., Deng M.W., Wu Y.H., Sung J.S., et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008, 99:905-913.
94. Sheshadri N., Catanzaro J.M., Bott A.J., Sun Y., Ullman E., Chen E.I., et al. SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling. Cancer Res 2014, 74:6318-6329.
95. Li L., Han R., Xiao H., Lin C., Wang Y., Liu H., et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin. Cancer Res 2014, 20:2714-2726.
96. Conze D., Weiss L., Regen P.S., Bhushan A., Weaver D., Johnson P., et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001, 61:8851-8858.
97. Sun X., Mao Y., Wang J., Zu L., Hao M., Cheng G., et al. IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene 2014, 33:4450.
98. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+breast cancer by expanding the cancer stem cell population. Mol. Cell 2012, 47:570-584.
99. Yamada D., Kobayashi S., Wada H., Kawamoto K., Marubashi S., Eguchi H., et al. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur. J. Cancer 2013, 49:1725-1740.
100. Wang Y., Qu Y., Zhang X.L., Xing J., Niu X.L., Chen X., et al. Autocrine production of interleukin-6 confers ovarian cancer cells resistance to tamoxifen via ER isoforms and SRC-1. Mol. Cell. Endocrinol 2014, 382:791-803.
101. Wang Y., Niu X.L., Qu Y., Wu J., Zhu Y.Q., Sun W.J., et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010, 295:110-123.
102. Engelman J.A., Janne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res 2008, 14:2895-2899.
103. Yao Z., Fenoglio S., Gao D.C., Camiolo M., Stiles B., Lindsted T., et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15535-15540.
104. Kim S.M., Kwon O.J., Hong Y.K., Kim J.H., Solca F., Ha S.J., et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR Inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther 2012, 11:2254-2264.
105. Yan H.Q., Huang X.B., Ke S.Z., Jiang Y.N., Zhang Y.H., Wang Y.N., et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation. Cancer Sci 2014, 105:1220-1227.
106. Hsu H.S., Lin J.H., Hsu T.W., Su K., Wang C.W., Yang K.Y., et al. Mesenchymal stem cells enhance lung cancer initiation through activation of IL-6/JAK2/STAT3 pathway. Lung Cancer 2012, 75:167-177.
107. Feng S., Tang Q., Sun M., Chun J.Y., Evans C.P., Gao A.C. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol. Cancer Ther 2009, 8:665-671.
108. Kutikov A., Makhov P., Golovine K., Canter D.J., Sirohi M., Street R., et al. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer. Urology 2011, 78.
109. Wu C.T., Chen M.F., Chen W.C., Hsieh C.C. The role of IL-6 in the radiation response of prostate cancer. Radiat. Oncol 2013, 8.
110. Chang P.C., Wang T.Y., Chang Y.T., Chu C.Y., Lee C.L., Hsu H.W., et al. Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells. PLoS ONE 2014, 9.
111. Liu Y., Li P.K., Li C.L., Lin J.Y. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J. Biol. Chem 2010, 285:27429-27439.
112. Bellone S., Watts K., Cane S., Palmieri M., Cannon M.J., Burnett A., et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol. Oncol 2005, 98:92-98.
113. Cherfils-Vicini J., Platonova S., Gillard M., Laurans L., Validire P., Caliandro R., et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest 2010, 120:1285-1297.
114. Cho H.Y., Lee S.W. TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells. Cell. Immunol 2014, 289:27-35.
115. Duan Z., Lamendola D.E., Penson R.T., Kronish K.M., Seide M.V. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-20S human osteosarcoma cells. Cytokine 2002, 17:234-242.
116. Lu Z.Y., Wang J.B., Zheng T.S., Liang Y.J., Yin D.L., Song R.P., et al. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer 2014, 14.
117. Sugimura K., Miyata H., Tanaka K., Hamano R., Takahashi T., Kurokawa Y., et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin. Cancer Res 2012, 18:5144-5153.
118. Shi Z., Yang W.M., Chen L.P., Yang D.H., Zhou Q., Zhu J., et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res. Treat 2012, 135:737-747.
119. Tamatani T., Azuma M., Ashida Y., Motegi K., Takashima R., Harada K., et al. Enhanced radiosensitization and chemosensitization in NF-kappa B-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-Fu-induced production,of Il-6 and Il-8. Int. J. Cancer 2004, 108:912-921.
120. Xiang M., Birkbak N.J., Vafaizadeh V., Walker S.R., Yeh J.E., Liu S.H., et al. STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-kappa B to IL-6 signaling axis and STAT3-Driven cancer phenotypes. Sci. Signal 2014, 7.
121. Zhang J.S., Ma L. MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metast. Rev 2012, 31:653-662.
122. Deng B., Zhang Y., Zhang S., Wen F., Miao Y., Guo K. MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. Tumour Biol 2015, 36:8065-8073.
123. Gwak J.M., Kim H.J., Kim E.J., Chung Y.R., Yun S., Seo A.N., et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res. Treat 2014, 147:39-49.
124. Zhang J., Jia J., Zhao L., Li X., Xie Q., Chen X., et al. Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Mol. Carcinog 2015.
125. Patel S.A., Bhambra U., Charalambous M.P., David R.M., Edwards R.J., Lightfoot T., et al. Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. Br. J. Cancer 2014, 111:2287-2296.
126. Li T., Li L., Li D., Wang S., Sun J. MiR-34a inhibits oral cancer progression partially by repression of interleukin-6-receptor. Int. J. Clin. Exp. Pathol 2015, 8:1364-1373.
127. Chiou G.Y., Chien C.S., Wang M.L., Chen M.T., Yang Y.P., Yu Y.L., et al. Epigenetic regulation of the miR142-3p/interleukin-6 circuit in glioblastoma. Mol. Cell 2013, 52:693-706.
128. Han M.L., Wang Y.M., Liu M.R., Bi X.K., Bao J.J., Zeng N., et al. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1a expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 2012, 103:1058-1064.
129. Loffler D., Brocke-Heidrich K., Pfeifer G., Stocsits C., Hackermuller J., Kretzschmar A.K., et al. Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110:1330-1333.
130. Li C.H., Xu F.Y., Chow S., Feng L., Yin D.L., Ng T.B., et al. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression. Eur. J. Cancer 2014, 50:2560-2569.
131. Bao B., Azmi A.S., Ali S., Ahmad A., Li Y.W., Banerjee S., et al. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Bba-Rev. Cancer 2012, 1826:272-296.
132. Rupaimoole R., Wu S.Y., Pradeep S., Ivan C., Pecot C.V., Gharpure K.M., et al. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat. Commun 2014, 5.
133. Bao B., Ali S., Ahmad A., Azmi A.S., Li Y.W., Banerjee S., et al. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, Which can be attenuated by CDF treatment. PLoS ONE 2012, 7.
134. Li P., Shan J.X., Chen X.H., Zhang D., Su L.P., Huang X.Y., et al. Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res 2015, 25:588-603.
135. Ma J., Dong C., Ji C. MicroRNA and drug resistance. Cancer Gene Ther 2010, 17:523-531.
136. Chen Z.L., Shi T.L., Zhang L., Zhu P.L., Deng M.Y., Huang C., et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett 2016, 370:153-164.
137. Wang Z.W., Li Y.W., Ahmad A., Azmi A.S., Kong D.J., Banerjee S., et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist. Update 2010, 13:109-118.
138. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 2014, 14:736-746.
139. Niu J., Xue A., Chi Y., Xue J., Wang W., Zhao Z., et al. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene 2015.
140. Giles K.M., Kalinowski F.C., Candy P.A., Epis M.R., Zhang P.M., Redfern A.D., et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol. Cancer Ther 2013, 12:2541-2558.
141. Wang Q., Wang Z., Chu L., Li X., Kan P., Xin X., et al. The Effects and molecular mechanisms of MiR-106a in multidrug resistance reversal in human glioma U87/DDP and U251/G cell lines. PLoS ONE 2015, 10:e0125473.
142. Ara T., Declerck Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur. J. Cancer 2010, 46:1223-1231.